MedTrace Logo

Diagnostic Accuracy of Gallium-68-DOTATATE PET/CT Compared to Indium-111-pentetreotide Scintigraphy (SPECT/CT) for Gastroenteropancreatic Neuroendocrine Tumors

NCT02078843 · Status: TERMINATED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 54

Last updated 2016-09-07

No results posted yet for this study

Summary

The investigators hypothesize that the new imaging method Gallium-68-DOTATATE has a higher diagnostic value in the detection of neuroendocrine tumors than the established imaging method Indium-111-Octreoscan. Therefore, the investigators will perform both imaging procedures in patients with suspected or confirmed neuroendocrine tumors. Subsequently, the investigators will compare the diagnostic performance of both methods.

Conditions

  • Gastroenteropancreatic Neuroendocrine Tumors

Interventions

DRUG

Gallium-68-DOTATATE PET/CT (index test)

Somatostatin-based imaging tracer

DRUG

Indium-111-Octreoscan (standard test)

Somatostatin-based imaging tracer

Sponsors & Collaborators

  • University of Lausanne Hospitals

    collaborator OTHER

  • University Hospital, Basel, Switzerland

    collaborator OTHER

  • University of Bern

    collaborator OTHER

  • SWAN Isotopen AG, Bern

    collaborator UNKNOWN

  • Insel Gruppe AG, University Hospital Bern

    lead OTHER

Principal Investigators

  • Thomas Krause, Prof. Dr. med. · Institute of Nuclear Medicine, University Hospital Berne

  • Christoph Stettler, Prof. Dr. med. · Division of Endocrinology, University Hospital Bern

Study Design

Allocation
NA
Purpose
DIAGNOSTIC
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-03-31
Primary Completion
2016-08-31
Completion
2016-08-31

Countries

  • Switzerland

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02078843 on ClinicalTrials.gov